Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Core Insights - Recursion is presenting updated safety and efficacy results from the ongoing Phase I/II TUPELO study evaluating REC-4881 for familial adenomatous polyposis (FAP) [1][2] - The company emphasizes the significant unmet medical need in FAP, which affects over 50,000 patients in the U.S. and EU5, with the potential for higher prevalence as diagnostic rates improve [3] Group 1: Study Results - The ongoing Phase Ib/II study has yielded positive results, showcasing emerging clinical evidence for REC-4881 [2] - The presentation aims to highlight the progress made by Recursion in developing treatments for rare diseases [2] Group 2: Unmet Need in FAP - FAP patients undergo a lifetime of escalating medical interventions, including frequent surveillance and surgeries, due to the absence of approved pharmacotherapies [3] - The natural history work conducted with the University of Amsterdam Medical Center supports the understanding of FAP's impact on patients [3]